Search
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigationalAbrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function. The Janus kinase (JAK)–signal trans...
Synonyms: PF-04965842Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsRelacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pi...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2C8 InducersDifamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigationalAtopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions. This skin disease occurs most frequently in children and can have an...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigationalAprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of macitentan. Approximately 10-15% of patients with hypertension have resistant hypertension, defin...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2C18 InhibitorsInavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigationalPIK3CA is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme InducersXanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigationalSchizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine. Positive symptoms (e.g. hallucinations, delusions) have traditionally been attributed to increased do...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS in...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigationalVasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are some of the most common symptoms in menopause. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesZavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigationalZavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways. CGRP receptors...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesIptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigationalIptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor B. Factor B is a positive regulato...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates